Jafron Biomedical Co (300529) Fair Value & Analysis
Healthcare · CN · Market cap 12.9B CNY
Fair value as of: Jul 9, 2026
From 24 valuation models · updated 32 days ago
Share price +1.0% over the past month.
A solid business, but screening 10% overvalued on our models.
What matters now
- A fairly wide model range (¥11.01 to ¥22.69) leaves room in how you read the outcome.
- Our model range runs from ¥11.01 (bear) to ¥22.69 (bull), base ¥14.68. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 71/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 9, 2026.
How to read this chart
60‑month range ¥15.04 – ¥90.02 · fair‑value band ¥11.01 – ¥22.69 · the ¥16.38 price screens above the ¥14.68 fair value. Dashed = 300-day average. As of Jul 9, 2026.
Analysis
Jafron Biomedical Co (300529) currently trades at ¥16.38, while our model-based Fair Value estimate is ¥14.68, implying the stock looks roughly 10.4% overvalued today. The Quality Score stands at 71/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Jafron Biomedical Co generated revenue of 2.0B CNY at a net margin of 27.9%. Revenue grew 2.3% year over year. It earns a return on equity of 15.6%. The balance sheet holds a net cash position of 532M CNY. Fundamentals as of Jul 9, 2026
Our scenario range runs from ¥11.01 (bear case) to ¥22.69 (bull case); at ¥16.38, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 32% below its 52-week high and 2% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -10%, 300529 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (¥22.71) versus Asset-Based (¥2.91). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 9, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 70 · Market factors (momentum, volatility) 35
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning.
Full company description
Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification machine; and other products, such as JM hemodialyzer, DNA230, disinfectant, hemodialysis concentrate, resin bandage, online hemodialysis B powder bag/bucket, PGA absorbable suture with needle, syringe and infusion pumps. The company was founded in 1989 and is based in Zhuhai, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Jafron Biomedical Co reported revenue of ¥2.0B in FY2025 versus ¥2.7B in FY2021, a compound −6.9%/yr. Reported net income was ¥533M in FY2025, compounding −18.3%/yr from FY2021.
300529 screens 10% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 351 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 45/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Jafron Biomedical Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Jafron Biomedical Co (300529) overvalued or undervalued?
What is the fair value of 300529?
What is the quality score of 300529?
What is the revenue of Jafron Biomedical Co (300529)?
What is the net profit margin of 300529?
Does Jafron Biomedical Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Jafron Biomedical Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.